Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
– 33 early and late-stage clinical programs across modalities and innovative discovery platforms
– Uniquely positioned to lead in Alzheimer’s disease with ADUHELM® (aducanumab-avwa) and industry-leading pipeline including Phase 3 lecanemab
– Potential to transform standard of care in several areas of high unmet need in depression, ALS, stroke and lupus
– Biomarkers and digital health to enable early diagnosis and personalized medicine
– Continued leadership in neuroscience sustained by distinct capabilities and talent
CAMBRIDGE, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq …
Read the source article at biospace.com
2021-09-21 04:00:00
